Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Cancer Discovery|January 5, 2022
Independent Drug Action in Combination Therapy: Implications for Precision OncologyDeborah Plana, Adam C Palmer, Peter K SorgerCell Systems|November 22, 2020
Comparing the Efficacy of Cancer Therapies between Subgroups in Basket TrialsAdam C Palmer, Deborah Plana, Peter K SorgerElife|November 20, 2019
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivityAdam C Palmer, Christopher Chidley, Peter K SorgerCancer Cell|September 29, 2023
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splitsCynthia K Hahn, Adam C Palmer, David M WeinstockTranscription|February 18, 2011
Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factorsAdam C Palmer, J Barry Egan, Keith E ShearwinBiorxiv : the Preprint Server for Biology|March 13, 2023
Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonismSarah C Patterson, Amy E Pomeroy, Adam C PalmerMolecular Cancer Therapeutics|June 15, 2026
Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma modelsJacob C Pantazis, Amy E Pomeroy, Adam C PalmerNature Communications|January 21, 2016
Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environmentsRemy Chait, Adam C Palmer, Idan Yelin, et al.Molecular Cancer Therapeutics|March 26, 2024
Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug AntagonismSarah C Patterson, Amy E Pomeroy, Adam C PalmerBiorxiv : the Preprint Server for Biology|November 24, 2025
Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphomaJacob C Pantazis, Amy E Pomeroy, Adam C PalmerPageof 5